Article
Detection of TP53 dysfunction in chronic lymphocytic leukemia by an in vitro functional assay based on TP53 activation by the non-genotoxic drug Nutlin-3: a proposal for clinical application.
Journal of hematology & oncology - 5 Nov 2013
Pozzo Federico, Dal Bo Michele, Peragine Nadia, Bomben Riccardo, Zucchetto Antonella, Rossi Francesca, Degan Massimo, Rossi Davide, Chiarenza Annalisa, Grossi Alberto, Di Raimondo Francesco, Zaja Francesco, Pozzato Gabriele, Secchiero Paola, Gaidano Gianluca, Del Poeta Giovanni, Zauli Giorgio, Fo À Robin, Guarini Anna, Gattei Valter
Abstract excerpt
BACKGROUND: TP53 defects, i.e., 17p13 deletion and/or nucleotide mutations, associate with short survival and chemorefractoriness in chronic lymphocytic leukemia (CLL). In this context, since direct sequencing of the TP53 gene does not evaluate TP53 functionality, a functional assessment of TP53 pathway may be of interest to identify high risk CLL. By taking advantage of a training cohort of 100 CLL and a...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.